Calliditas Therapeutics AB
STO:CALTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100.3
208.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Calliditas Therapeutics AB
Calliditas Therapeutics AB
Net Income (Common)
Calliditas Therapeutics AB
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Net Income (Common)
-kr480.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
Orexo AB
STO:ORX
|
Net Income (Common)
-kr105.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Camurus AB
STO:CAMX
|
Net Income (Common)
kr266.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Net Income (Common)
kr76.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Net Income (Common)
-kr177.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Net Income (Common)
-kr269.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Calliditas Therapeutics AB
Glance View
Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions. Their flagship product, Nefecon, is a testament to their approach—designed to treat primary IgA nephropathy, a debilitating kidney disorder. By developing Nefecon with a patient-centric mindset, Calliditas aims to transform the treatment landscape, showcasing its commitment to innovation and regulatory expertise. Revenue generation at Calliditas primarily revolves around the commercialization of its niche therapeutic solutions. The company operates through a well-structured business model that includes strategic partnerships, licensing agreements, and direct market entry. Profits are garnered through successfully translating their clinical research into approved drugs that address critical needs in the healthcare sector. In tandem with developing their portfolio, Calliditas maximizes opportunities within established and emerging markets, ensuring that their highly specialized medicines reach the patients who need them most. This strategic focus not only secures their financial standing but also emphasizes their pivotal role as a pivotal player in rare disease treatment. The resultant revenue stream and successful collaborations underscore Calliditas's capability to marry scientific advancement with commercial viability, ensuring sustainable growth in a competitive pharmaceutical landscape.
See Also
What is Calliditas Therapeutics AB's Net Income (Common)?
Net Income (Common)
-480.4m
SEK
Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Net Income (Common) amounts to -480.4m SEK.
What is Calliditas Therapeutics AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-69%
Over the last year, the Net Income (Common) growth was -64%. The average annual Net Income (Common) growth rates for Calliditas Therapeutics AB have been 7% over the past three years , -69% over the past five years .
You don't have any saved screeners yet
